Showing 7231-7240 of 9760 results for "".
- Physician Assistant Groups Respond to JAMA Dermatology Study: "Fundamentally Flawed"https://practicaldermatology.com/news/physician-assistant-groups-respond-to-jama-dermatology-study-fundamentally-flawed/2457798/The American Academy of PAs (AAPA) and the Society of Dermatology PAs (SDPA) have issued a statemen
- Tattoo Removal Misperceptions Aboundhttps://practicaldermatology.com/news/tattoo-removal-misperceptions-abound/2457807/More than four in five adults with (86 percent) and without (82 percent) tattoos have misconceptions about tattoo removal, including confusion regarding side effects, cost and removability, according to a new Merz survey. In addition to not knowing how the process works, many underestimat
- New JAMA Dermatology Publication Features AID Accelerator Fund to Enable Progress of Promising Early-stage Scientific Technologieshttps://practicaldermatology.com/news/new-jama-dermatology-publication-features-aid-accelerator-fund-to-enable-progress-of-promisingearly-stage-scientific-technologies/2457810/A new article, "Catalyzing Future Drug, Device, and Information Technology Breakthroughs in Dermatology", in JAMA Dermatology features the Advancing Innovation in Dermatology (AID) Accelerator Fund. AID has created this mechanism to help enable and speed the product development
- Coming Soon to a City Near You: Sciton Inc.'s Bright Lights Big City BBL 2018 Tourhttps://practicaldermatology.com/news/coming-soon-to-a-city-near-you-sciton-incs-bright-lights-big-city-bbl-2018-tour/2457815/Sciton. Inc.’s Bright Lights Big City BroadBand Light (BBL) 2018 Tour is now in its third year. The 2018 Tour, featuring San Francisco dermatologist Patrick Bitter Jr., MD, kicks off in early June in For
- ASDSA Applauds USPSTF Endorsement of Behavioral Counseling to Prevent Skin Cancerhttps://practicaldermatology.com/news/asdsa-applauds-uspstf-endorsement-of-behavioral-counseling-to-prevent-skin-cancer/2457820/The American Society for Dermatologic Surgery Association (ASDSA) applauds the recent US Preventive Service Task Force (USPSTF) endorsement of behavioral counseling to prevent skin cancer for individuals aged six months to 24 years
- American Academy of Dermatology Elects New Officers, Board Membershttps://practicaldermatology.com/news/american-academy-of-dermatology-elects-new-officers-board-members/2457825/The American Academy of Dermatology named its new officers and board members who will represent the more than 19,000 physicians who specialize in the diagnosis and medical, surgical and cosmetic treatment of skin, hair, and nail conditions. These officers and board members, all of whom are board-
- Researchers Assess Tools to Measure QoL Impact of Skin Conditionshttps://practicaldermatology.com/news/researchers-assess-tools-to-measure-qol-impact-of-skin-conditions/2457827/Boston University School of Medicine researchers have set out to find the best tool to measure the impact of skin coniditons on patients' quality of life. Several dermatology and disease-specific tools have been developed to measure the impact of skin disease including the widel
- EpigenCare Named as Johnson & Johnson Innovation Finalist in Skincare Challengehttps://practicaldermatology.com/news/epigencare-named-as-johnson-johnson-innovation-finalist-in-skincare-challenge/2457829/EpigenCare Inc., a personalized skincare startup company, is a finalist in Johnson & Johnson Innovation’s Digital Beauty Quickfire Challenge. The Challenge
- Did New USPSTF Recommendations on Skin Cancer Prevention Counseling Go Far Enough? AADA Reactshttps://practicaldermatology.com/news/did-new-uspstf-recommendations-on-skin-cancer-prevention-counselling-go-far-enough-aada-reacts/2457830/The U.S. Preventive Services Task Force (USPSTF) is calling for behavioral counseling to help reduce the risk of skin cancer from ultraviolet (UV) radiation in people aged 6 months to 24 years with fair skin types. The new USPSTF recommendation statement updates a 2012 recommendation on b
- Sun Pharma: FDA Approves Ilumya for Adult Psoriasishttps://practicaldermatology.com/news/sun-pharma-fda-approves-ilumya-for-adult-psoriasis/2457831/The FDA has approved Ilumya™ (tildrakizumab-asmn) from Sun Pharma for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Ilumya selectively binds to the p19 subunit of IL-23 a